Intravenous Tigecycline As Adjunctive or Alternative Therapy for Severe Refractory Clostridium Difficile Infection

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2009 May 14

PMID 19435431

Citations 49

Authors

Bjorn L Herpers

Bart Vlaminckx

Olaf Burkhardt

Harmjo Blom

Hazra S Biemond-Moeniralam

Mathias Hornef

Tobias Welte

Edward J Kuijper

Affiliations

Soon will be listed here.

Abstract

Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.

Citing Articles

A Review of Therapies for Infection.

Morado F, Nanda N Antibiotics (Basel). 2025; 14(1).

PMID: 39858303 PMC: 11762378. DOI: 10.3390/antibiotics14010017.

Improving Infectious Disease Treatment Response via Adherence to Clinical Practice Guidelines.

Adukauskiene D, Mickus R, Dambrauskiene A, Vanagas T, Adukauskaite A Antibiotics (Basel). 2024; 13(1).

PMID: 38247610 PMC: 10812669. DOI: 10.3390/antibiotics13010051.

Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.

Phillips E, Warren C, Ma J, Madden G Antimicrob Agents Chemother. 2022; 66(6):e0000122.

PMID: 35647645 PMC: 9211400. DOI: 10.1128/aac.00001-22.

Calculated initial parenteral treatment of bacterial infections: Bacterial gastrointestinal infections.

Mutters R, Walger P, Lubbert C GMS Infect Dis. 2020; 8:Doc06.

PMID: 32373431 PMC: 7186808. DOI: 10.3205/id000050.

Clostridioides difficile associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges.

Shah K, Cherabuddi K, Pressly K, Wright K, Shukla A BMC Nephrol. 2020; 21(1):76.

PMID: 32131755 PMC: 7055046. DOI: 10.1186/s12882-020-01734-8.